Notice: This company has been marked as potentially delisted and may not be actively trading. (ANTX) (ANTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesTrends ANTX vs. TSVT, SGMT, IVA, RENB, TELO, MIST, VTYX, VIRI, IFRX, and EPRXShould you be buying (ANTX) stock or one of its competitors? The main competitors of (ANTX) include 2seventy bio (TSVT), Sagimet Biosciences (SGMT), Inventiva (IVA), Renovaro (RENB), Telomir Pharmaceuticals (TELO), Milestone Pharmaceuticals (MIST), Ventyx Biosciences (VTYX), Virios Therapeutics (VIRI), InflaRx (IFRX), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical preparations" industry. (ANTX) vs. 2seventy bio Sagimet Biosciences Inventiva Renovaro Telomir Pharmaceuticals Milestone Pharmaceuticals Ventyx Biosciences Virios Therapeutics InflaRx Eupraxia Pharmaceuticals 2seventy bio (NASDAQ:TSVT) and (ANTX) (NYSE:ANTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Is TSVT or ANTX more profitable? (ANTX) has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. 2seventy bio's return on equity of -53.65% beat (ANTX)'s return on equity.Company Net Margins Return on Equity Return on Assets 2seventy bio-207.25% -53.65% -23.67% (ANTX) N/A -57.62%-52.08% Does the media refer more to TSVT or ANTX? In the previous week, 2seventy bio had 3 more articles in the media than (ANTX). MarketBeat recorded 4 mentions for 2seventy bio and 1 mentions for (ANTX). 2seventy bio's average media sentiment score of 0.15 beat (ANTX)'s score of 0.00 indicating that 2seventy bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 2seventy bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral (ANTX) 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in TSVT or ANTX? 93.9% of 2seventy bio shares are held by institutional investors. Comparatively, 90.5% of (ANTX) shares are held by institutional investors. 7.2% of 2seventy bio shares are held by company insiders. Comparatively, 20.8% of (ANTX) shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer TSVT or ANTX? 2seventy bio currently has a consensus target price of $7.20, suggesting a potential upside of 175.86%. (ANTX) has a consensus target price of $2.67, suggesting a potential upside of 134.33%. Given 2seventy bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe 2seventy bio is more favorable than (ANTX).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 2seventy bio 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50(ANTX) 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor TSVT or ANTX? (ANTX) received 71 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 58.54% of users gave (ANTX) an outperform vote while only 52.08% of users gave 2seventy bio an outperform vote. CompanyUnderperformOutperform2seventy bioOutperform Votes2552.08% Underperform Votes2347.92% (ANTX)Outperform Votes9658.54% Underperform Votes6841.46% Which has more volatility & risk, TSVT or ANTX? 2seventy bio has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, (ANTX) has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Which has higher valuation and earnings, TSVT or ANTX? (ANTX) has lower revenue, but higher earnings than 2seventy bio. 2seventy bio is trading at a lower price-to-earnings ratio than (ANTX), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio2seventy bio$100.39M1.34-$217.57M-$1.86-1.40(ANTX)N/AN/A-$64.73M-$2.04-0.56 Summary2seventy bio beats (ANTX) on 12 of the 17 factors compared between the two stocks. Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANTX vs. The Competition Export to ExcelMetric(ANTX)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$33.76M$7.06B$5.84B$20.30BDividend YieldN/A2.75%4.75%3.64%P/E RatioN/A5.7326.0434.82Price / SalesN/A306.03447.4615.49Price / CashN/A65.6738.0120.26Price / Book0.276.717.644.80Net Income-$64.73M$138.33M$3.18B$1.02B (ANTX) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANTX(ANTX)2.5808 of 5 stars$1.14-6.7%$2.67+134.3%-65.8%$33.76MN/A0.00N/ATSVT2seventy bio2.1813 of 5 stars$2.54-0.4%$7.20+183.5%-53.2%$131.03M$45.62M-1.37440Analyst ForecastNews CoverageSGMTSagimet Biosciences1.8145 of 5 stars$4.25-3.4%$23.00+441.2%-38.9%$130.35M$2M0.008IVAInventiva2.0097 of 5 stars$2.47-0.4%$13.25+436.4%-13.1%$129.63M$18.91M0.00100Analyst ForecastNews CoverageGap UpRENBRenovaro0.763 of 5 stars$0.81+9.0%N/A-61.1%$128.39MN/A-0.8420Earnings ReportNews CoverageGap UpTELOTelomir Pharmaceuticals2.2818 of 5 stars$4.29+0.5%N/A-54.8%$127.67MN/A-7.401Analyst ForecastNews CoverageMISTMilestone Pharmaceuticals2.8119 of 5 stars$2.27-0.9%$13.00+472.7%+29.1%$121.06M$1M-2.8030VTYXVentyx Biosciences3.1131 of 5 stars$1.71+1.8%$10.00+484.8%-68.1%$120.92MN/A-0.7230Upcoming EarningsVIRIVirios TherapeuticsN/A$6.13-8.6%$3.00-51.1%+1,411.6%$118.05MN/A-22.705IFRXInflaRx3.2978 of 5 stars$2.00-25.9%$8.00+300.0%+21.9%$117.76M$70,000.00-1.8560Gap DownHigh Trading VolumeEPRXEupraxia Pharmaceuticals3.4167 of 5 stars$3.28+1.2%$9.00+174.4%N/A$116.83MN/A-4.5629Analyst ForecastShort Interest ↓News CoverageHigh Trading Volume Related Companies and Tools Related Companies TSVT Competitors SGMT Competitors IVA Competitors RENB Competitors TELO Competitors MIST Competitors VTYX Competitors VIRI Competitors IFRX Competitors EPRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ANTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ANTX) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ANTX) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANTX Stock Alerts